Shanghai OriginCell Therapeutics Co., Ltd. Report issue

For profit Phase 1
Founded: Shanghai China (2014)

Organization Overview

First Clinical Trial
2020
NCT04674488
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shanghai OriginCell Therapeutics Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

autologous tumor infiltrating lymphocytes (2 trials)

gprc5d-car-t (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Uterine Cervical Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2